How to Conduct a DPIA: Best Practices for Small Biopharma
Data Protection Impact Assessments (DPIAs) are essential tools for identifying and managing privacy risks, particularly when handling sensitive health data in clinical trials and research. For small biopharma companies, conducting a DPIA is critical for ensuring compliance with the General Data Protection Regulation (GDPR) while building trust with trial participants. By adhering to best practices, these companies can effectively balance privacy protection with limited resources. Here’s how small biopharma companies can perform efficient and effective DPIAs.
1. Understand When a DPIA is Required
Under Article 35 of the GDPR, a DPIA is mandatory when data processing is "likely to result in a high risk" to individuals’ rights and freedoms. In the biopharma context, this often applies to clinical trials due to the processing of sensitive health data, the large volume of data, and potential restrictions on participant rights, such as the limitations to delete personal data.
Small biopharma companies should proactively assess their data processing activities to determine whether they meet the criteria for a DPIA. Early identification ensures better planning, reduces delays in compliance, and allows for smoother project execution.
2. Set Clear Objectives for the DPIA
The primary goal of a DPIA is to identify privacy risks, evaluate their potential impact, and propose measures to mitigate those risks. For small biopharma companies, it also provides an opportunity to refine internal practices, align with ethical research standards, and avoid the reputational damage of privacy breaches. Clearly defining the scope and objectives of the DPIA ensures that efforts remain focused and effective.
3. Assemble the Right Team
A DPIA is a collaborative effort. Even for small companies, it’s crucial to involve key stakeholders, including:
Data Protection Officer (DPO) (if appointed).
Representatives from clinical operations and IT teams.
External consultants with expertise in biopharma and GDPR compliance, if internal resources are limited.
Each participant brings unique insights into identifying risks and crafting mitigation strategies tailored to the clinical trial environment.
4. Map Data Flows and Processing Activities
Start by mapping out every stage of your data processing activities, including data collection, storage, sharing, and analysis. For biopharma companies, this typically includes:
Patient recruitment.
Data monitoring during trials.
Sharing data with regulators, sponsors, and research partners.
Documenting data flows highlights potential vulnerabilities and provides a foundation for evaluating risks. It also ensures compliance with GDPR’s transparency principle, demonstrating to stakeholders that data is handled responsibly.
5. Identify and Assess Privacy Risks
Analyzing risks is the core of the DPIA process. Common risks in biopharma research include:
Unauthorized access to data.
Data breaches during transfers to research partners or regulators.
Insufficient participant consent procedures.
Misuse of sensitive health data.
For each risk, assess its likelihood and potential impact on data subjects. Small biopharma companies should pay particular attention to risks arising from their reliance on third-party vendors for trial-related activities.
6. Define Mitigating Actions
Once risks are identified, outline specific measures to address them. Common mitigation strategies include:
Data Minimization: Only collect data essential for trial objectives.
Pseudonymization/Anonymization: Remove identifiers wherever possible.
Access Controls: Restrict access to authorized personnel and enforce strict protocols.
Encryption: Secure sensitive data both at rest and in transit.
Tailoring these measures to the unique requirements of your trial ensures cost-effectiveness and regulatory compliance.
7. Review Legal and Regulatory Requirements
A successful DPIA aligns not only with GDPR requirements but also with industry-specific regulations. For biopharma companies, this means considering guidelines from bodies like the European Medicines Agency (EMA) or local health authorities. Consulting experts familiar with both GDPR and clinical trial standards ensures full compliance and minimizes legal risks.
8. Document the DPIA Process Thoroughly
GDPR requires that companies document DPIAs in detail, including the decisions made and reasons for selecting specific mitigating measures. A thorough record not only demonstrates compliance but also serves as a reference for future DPIAs. In small companies, this documentation can be especially valuable for scaling privacy processes as the business grows.
9. Establish a Monitoring Plan
Completing a DPIA isn’t the end—it’s the beginning of ongoing monitoring. Assign responsibility to a specific team or individual to regularly review processing activities, especially when:
New data processing activities are introduced.
The scope or nature of the trial changes.
New privacy risks emerge.
Regular updates ensure that mitigation measures remain effective and that your company stays ahead of regulatory changes.
Conclusion
For small biopharma companies, conducting a DPIA is not just a compliance exercise; it’s a vital step in ensuring ethical research and building participant trust. By following these best practices—setting clear objectives, assembling the right team, mapping data flows, identifying risks, and monitoring over time—companies can protect sensitive data and foster credibility in the competitive biopharma landscape. DPIAs are not just about avoiding fines; they are an investment in ethical innovation and long-term success.
Best,
Diana
At RD Privacy, we specialize in helping biopharma companies navigate the complexities of GDPR compliance. Whether you're conducting your first DPIA or looking to enhance your existing privacy processes, our team can provide the guidance you need.
📧 Contact us today to learn how we can support your clinical research initiatives and ensure compliance with global data protection standards.
🔗 Visit us to explore our services and resources tailored for the biopharma industry.
Together, let’s build trust, ensure compliance, and support ethical innovation in clinical research.
